drugset / Trial / NCT06547736
Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of ADC drugs monotherapy or combination therapy with HRS-4642 or immunotherapy in subjects with locally advanced or metastatic pancreatic cancer.
Timeline
- Start
- 2024-10-14
- Primary completion
- 2027-03
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | HRS-4642 | Unknown | — | — |
| Subject | SHR-A1811 | Monoclonal antibody | — | — |
| Subject | SHR-A1904 | Unknown | — | — |
| Subject | SHR-A2102 | Other / unclassified | — | — |